At a glance
- Originator Praecis Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 27 May 2005 Suspended - Phase-I/II for Alzheimer's disease in USA (IV)
- 08 Feb 2005 PPI 1019 (Apan™) is available for licensing beyond phase I development (http://www.praecis.com)
- 31 Jan 2005 Praecis Pharmaceuticals has initiated enrolment in the multiple dose escalation, phase I/IIa trial for Alzheimer's disease in USA